Joint Filing AgreementJoint Filing Agreement • March 28th, 2024 • Velan Capital Investment Management LP • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on Schedule 13G dated March 28, 2024 with respect to the Common Stock, par value $0.01 per share, of Outlook Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
